| A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable A Cortellini, M Bersanelli, S Buti, K Cannita, D Santini, F Perrone, R Giusti, ... Journal for immunotherapy of cancer 7, 1-11, 2019 | 375 | 2019 |
| Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non–small cell lung cancer B Shankar, J Zhang, AR Naqash, PM Forde, JL Feliciano, KA Marrone, ... JAMA oncology 6 (12), 1952-1956, 2020 | 374 | 2020 |
| Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional … B Ricciuti, C Genova, A De Giglio, M Bassanelli, MG Dal Bello, G Metro, ... Journal of cancer research and clinical oncology 145, 479-485, 2019 | 331 | 2019 |
| Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression EJ Aguilar, B Ricciuti, JF Gainor, KL Kehl, S Kravets, S Dahlberg, ... Annals of Oncology 30 (10), 1653-1659, 2019 | 322 | 2019 |
| Immune checkpoint inhibitor outcomes for patients with non–small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications B Ricciuti, SE Dahlberg, A Adeni, LM Sholl, M Nishino, MM Awad Journal of Clinical Oncology 37 (22), 1927-1934, 2019 | 272 | 2019 |
| Diminished efficacy of programmed death-(ligand) 1 inhibition in STK11-and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status B Ricciuti, KC Arbour, JJ Lin, A Vajdi, N Vokes, L Hong, J Zhang, ... Journal of Thoracic Oncology 17 (3), 399-410, 2022 | 269 | 2022 |
| Association of high tumor mutation burden in non–small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 … B Ricciuti, X Wang, JV Alessi, H Rizvi, NR Mahadevan, YY Li, A Polio, ... JAMA oncology 8 (8), 1160-1168, 2022 | 231 | 2022 |
| Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis H Abu-Sbeih, FS Ali, AR Naqash, DH Owen, S Patel, GA Otterson, ... Journal of clinical oncology 37 (30), 2738-2745, 2019 | 186 | 2019 |
| Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14–mutant NSCLC G Recondo, M Bahcall, LF Spurr, J Che, B Ricciuti, GC Leonardi, YC Lo, ... Clinical Cancer Research 26 (11), 2615-2625, 2020 | 178 | 2020 |
| Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease H Abu-Sbeih, DM Faleck, B Ricciuti, RB Mendelsohn, AR Naqash, ... Journal of Clinical Oncology 38 (6), 576-583, 2020 | 176 | 2020 |
| Long noncoding RNAs: new insights into non-small cell lung cancer biology, diagnosis and therapy B Ricciuti, C Mencaroni, L Paglialunga, F Paciullo, L Crino, R Chiari, ... Medical oncology 33, 1-12, 2016 | 174 | 2016 |
| Clinical outcomes of patients with advanced cancer and pre‐existing autoimmune diseases treated with anti‐programmed death‐1 immunotherapy: a real‐world transverse study A Cortellini, S Buti, D Santini, F Perrone, R Giusti, M Tiseo, M Bersanelli, ... The oncologist 24 (6), e327-e337, 2019 | 166 | 2019 |
| Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients A Cortellini, R Chiari, B Ricciuti, G Metro, F Perrone, M Tiseo, M Bersanelli, ... Clinical lung cancer 20 (4), 237-247. e1, 2019 | 161 | 2019 |
| Endothelial and cardiac progenitor cells for cardiovascular repair: a controversial paradigm in cell therapy V Bianconi, A Sahebkar, P Kovanen, F Bagaglia, B Ricciuti, P Calabrò, ... Pharmacology & therapeutics 181, 156-168, 2018 | 145 | 2018 |
| Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L) 1 immune checkpoint inhibition in non–small cell lung cancer B Ricciuti, G Recondo, LF Spurr, YY Li, G Lamberti, D Venkatraman, ... Clinical cancer research 26 (15), 4135-4142, 2020 | 134 | 2020 |
| Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC) B Ricciuti, G Jones, M Severgnini, JV Alessi, G Recondo, M Lawrence, ... Journal for immunotherapy of cancer 9 (3), 2021 | 133 | 2021 |
| Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC A Keegan, B Ricciuti, P Garden, L Cohen, R Nishihara, A Adeni, ... Journal for immunotherapy of cancer 8 (2), 2020 | 130 | 2020 |
| Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study CA Nebhan, A Cortellini, W Ma, T Ganta, H Song, F Ye, R Irlmeier, ... JAMA oncology 7 (12), 1856-1861, 2021 | 122 | 2021 |
| Association between smoking history and tumor mutation burden in advanced non–small cell lung cancer X Wang, B Ricciuti, T Nguyen, X Li, MS Rabin, MM Awad, X Lin, ... Cancer research 81 (9), 2566-2573, 2021 | 119 | 2021 |
| Optimizing the safety of antibody–drug conjugates for patients with solid tumours P Tarantino, B Ricciuti, SM Pradhan, SM Tolaney Nature reviews Clinical oncology 20 (8), 558-576, 2023 | 112 | 2023 |
